Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...
Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...
Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...
A proposed model illustrating how tumor cells release PD-L1-containing small extracellular vesicles (sEVs) that suppress ...
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with ...
PD-L1 expression predicts better outcomes with nivolumab and ipilimumab in ccRCC, aligning with previous trial results. High KIM-1 expression is linked to worse DFS, suggesting its potential as a ...
Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
The Sydney-based oncology company revealed that NDL2 is designed to eliminate nuclear PD-L1, which Kazia identified as a previously unrecognized driver of immunotherapy resistance and metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results